This trial is testing whether it is safe to reduce the time patients are on two blood-thinning medications after having a coronary stent placed.
- Bleeding Complications
1 Primary · 0 Secondary · Reporting Duration: Through study completion, approximately 90 days.
2 Treatment Groups
1 of 2
1 of 2
150 Total Participants · 2 Treatment Groups
Primary Treatment: Tricagrelor · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals have enrolled in the research trial?
"Confirmed. The clinical trial is actively recruiting according to the data hosted on clinicaltrials.gov, which was first posted on March 29th 2022 and most recently updated October 24th 2022. 150 prospective participants are needed from a single medical facility." - Anonymous Online Contributor
Is enrollment in this research study still a viable option for those seeking treatment?
"Affirmative. Details obtained from clinicaltrials.gov demonstrate that the clinical trial, which was first advertised on March 29th 2022, is actively recruiting patients. 150 volunteers are required at a single location to participate in this research endeavour." - Anonymous Online Contributor
Is the drug Tricagrelor officially certified by the FDA?
"As this is a phase 4 trial, there are numerous studies that have validated tricagrelor's safety and efficacy; thus we assign it a score of 3." - Anonymous Online Contributor